Main baseline demographic and clinical characteristics of the patients treated with BsAbs from the total cohort
| . | % (range) . | Total (N = 109), n/N . |
|---|---|---|
| Age, median (range) | 61.83 (30-86) | |
| Sex | ||
| Male | 58.7 | 64/109 |
| Female | 41.3 | 45/109 |
| Diagnosis | ||
| Diffuse large B-cell lymphoma | 73.4 | 80/109 |
| FL | 18.3 | 20/109 |
| MCL | 5.5 | 6/109 |
| Chronic lymphocytic leukemia | 0.9 | 1/109 |
| Primary mediastinal B-cell lymphoma | 0.9 | 1/109 |
| Richter syndrome | 0.9 | 1/109 |
| No. previous lines, median (range) | 2.0 (0.0-9.0) | |
| Previous rituximab or in combination <6 months | ||
| No | 44.0 | 48/109 |
| Yes | 56.0 | 61/109 |
| Previous CAR T-cell therapy <6 months | ||
| No | 79.8 | 94/109 |
| Yes | 13.7 | 15/109 |
| Previous ASCT | ||
| No | 89.9 | 98/109 |
| Yes | 10.1 | 11/109 |
| BiTE combination agent | ||
| No combination | 57.8 | 63/109 |
| Chemotherapy | 11.0 | 12/109 |
| Immunotherapy | 31.2 | 34/109 |
| Vaccination | ||
| Unknown | 0.9 | 1/109 |
| No | 20.2 | 22/109 |
| Yes | 78.9 | 86/109 |
| No. of doses, median (range) | 3.0 (0.0-5.0) | |
| AZD7442 administration | ||
| No | 79.8 | 87/109 |
| Yes | 20.2 | 22/109 |
| Seroconversion | ||
| Not available | 30.3 | 33/109 |
| No | 25.7 | 28/109 |
| Yes | 44.0 | 48/109 |
| Follow-up, median (range), months | 34.3 (1-35.3) |
| . | % (range) . | Total (N = 109), n/N . |
|---|---|---|
| Age, median (range) | 61.83 (30-86) | |
| Sex | ||
| Male | 58.7 | 64/109 |
| Female | 41.3 | 45/109 |
| Diagnosis | ||
| Diffuse large B-cell lymphoma | 73.4 | 80/109 |
| FL | 18.3 | 20/109 |
| MCL | 5.5 | 6/109 |
| Chronic lymphocytic leukemia | 0.9 | 1/109 |
| Primary mediastinal B-cell lymphoma | 0.9 | 1/109 |
| Richter syndrome | 0.9 | 1/109 |
| No. previous lines, median (range) | 2.0 (0.0-9.0) | |
| Previous rituximab or in combination <6 months | ||
| No | 44.0 | 48/109 |
| Yes | 56.0 | 61/109 |
| Previous CAR T-cell therapy <6 months | ||
| No | 79.8 | 94/109 |
| Yes | 13.7 | 15/109 |
| Previous ASCT | ||
| No | 89.9 | 98/109 |
| Yes | 10.1 | 11/109 |
| BiTE combination agent | ||
| No combination | 57.8 | 63/109 |
| Chemotherapy | 11.0 | 12/109 |
| Immunotherapy | 31.2 | 34/109 |
| Vaccination | ||
| Unknown | 0.9 | 1/109 |
| No | 20.2 | 22/109 |
| Yes | 78.9 | 86/109 |
| No. of doses, median (range) | 3.0 (0.0-5.0) | |
| AZD7442 administration | ||
| No | 79.8 | 87/109 |
| Yes | 20.2 | 22/109 |
| Seroconversion | ||
| Not available | 30.3 | 33/109 |
| No | 25.7 | 28/109 |
| Yes | 44.0 | 48/109 |
| Follow-up, median (range), months | 34.3 (1-35.3) |
ASCT, autologous SCT; BiTE, bispecific T-cell engager.